000			02415na a2200253 4500
003			H12O
005			20180417112602.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_9387 _aCortijo Cascajares, Susana _eFarmacia
100			_9875 _aHerreros de Tejada López-Coterilla, Alberto _eFarmacia
100			_9385 _aJiménez Cerezo, María Jesús _eFarmacia
245	0	0	_aRevisión de las reacciones de hipersensibilidad a antineoplásicos _h[artículo]
260			_bFarmacia Hospitalaria, _c2012
300			_a36(3):148-158.
500			_aFormato Vancouver: Cortijo-Cascajares S, Jiménez-Cerezo MJ, Herreros de Tejada A. Revisión de las reacciones de hipersensibilidad a antineoplásicos. Farm Hosp. 2012;36(3):148-58.
501			_aPMID: 22484106
504			_aContiene 105 referencias
520			_aOBJECTIVE: To review the characteristics and management of hypersensitivity reactions caused by antineoplastic agents. METHOD: We conducted a search in the Pubmed and EMBASE databases for the last 10 years. RESULTS: Almost all chemotherapeutic agents have the potential to cause hypersensitivity reactions, but some groups have been associated with increased risk, such as platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins. The clinical manifestations of these reactions are variable and unpredictable, including symptoms affecting the skin and the pulmonary, cardiac and gastrointestinal systems. The mechanism associated with their development is not yet fully understood. Diagnosis is based on patients' signs and symptoms and skin testing. The management of patients who suffer a hypersensitivity reaction to a chemotherapeutic agent varies with the severity of the reaction, the need to continue treatment, and the availability of alternative therapies. CONCLUSIONS: Due to a progressive increase in the use of chemotherapeutic agents an increased incidence of hypersensitivity reactions is to be expected. Desensitisation protocols are a noteworthy alternative that make it possible to re-initiate patients' therapy with the causative agent of the hypersensitivity reaction. Their use should be assessed individually, weighing risks and benefits.
710			_9320 _aServicio de Farmacia Hospitalaria
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/6/pc699.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c699 _d699